Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program.

CONCLUSIONS: The results of this study indicate that the addition of ivabradine to an SoC treatment regimen for patients with HF may lead to a reduction in the penalties incurred by hospitals under the HRRP. This highlights the role ivabradine can play as part of a wider effort to optimize the care of patients with HF.
PMID: 27733074 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - October 14, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research